Specialized Biotics is built as one compounding S-curve: synbiotic revenue funds the data platform, the data platform de-risks precision biotics, and precision biotics open the door to pharma licensing.
Since 2022, major pharmaceutical companies have paid for microbiome assets across autoimmunity, oncology, infection and metabolic disease — independent validation of the category, ahead of our own results.
First-in-class synbiotics with engrafting capability. Early revenue, and the start of our real-world dataset.
Longitudinal microbiome and clinical data becomes a discovery engine and a clinical de-risking layer for drug development.
Efficacy signals from real human data support bacteria or metabolites advancing into pharma-licensed drug candidates.
The only synbiotic approach on the market with sustained, measurable strain engraftment.
A proprietary, compounding dataset that gets more valuable with every product cycle and every user.
Clinical, scientific and business strategy advisors from Harvard, the Broad Institute and Wharton.
Pre-seed (2025–26) is complete, with a lead investor in place for the current round.
Manufacturing, inventory, regulatory and promotion for our Gen 1 product line. (22% of round)
Clinical data collection and AI infrastructure, including data security and compliance. (38% of round)
Primarily scientists and consultants, plus general and administrative costs. (40% of round)
$10M revenue
$50M revenue
$50–80M revenue
Reach out and we’ll set up time to walk through the model in detail.